Archived Webinar: Infectious and Other Complications of Immunobiologic Agents Used by HIV-Infected Individuals
Thursday, May 10, 2018
Release date: May 10, 2018
Expiration date: May 10, 2019
CME Credit Available: 1.25 AMA PRA Category 1 Credits™
Assessment of Needs
As the HIV population ages, the risk of autoimmune diseases and malignancies is increasing. Since the late 1990s, advances in immunoregulatory cytokines or immune cells have revolutionized treatment. The pace of drug development in this area has only accelerated in recent years and a wider swath of patients with a variety of diseases are eligible for therapy. These include HIV-infected patients with rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and an increasing number of other diseases including malignancies. When immunoregulatory molecules are targeted and blocked, infectious, and further autoimmune and malignant consequences can arise. Clinicians should be aware of specific opportunistic infections that may occur with these agents, know strategies to mitigate this risk, and devise ways to discuss risks with patients.
On completion of this webinar, learners will be able to:
- List the types of conditions for which biologic agents may be prescribed for people with HIV infection
- Explain the mechanism of action of these agents to a patient in your practice so that he or she may understand why certain opportunistic infections and other complications may arise
- Describe the array of infectious and other complications that may arise with these agents
- Design strategies that you can use in clinic to prevent infectious and other complications in your patients
Who Should Attend
This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.